Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Can roflumilast become steroid-sparing alternative in the treatment of COVID-19?

Chirag A. Shah
Community Welfare Foundation India, Sangli 416416, India

A B S T R A C T

According to WHO the worst of the COVID-19 pandemic is yet to come. Despite of the exceptional measures being undertaken by regulatory agencies to expedite vaccine development, we may be several months if not years away from an effective vaccine. In such unprecedented times, the only resort nations have at their disposal is to identify and repurpose existing drugs against COVID-19 based on their known clinical or pharmacological profile which can provide direct or corroborative evidence of favorable benefit: risk in the management of COVID-19. Immune-mediated inflammation remains the hallmark of severe complications related to COVID-19 and while corticosteroids have shown preliminary evidence of benefit, they can act like a double-edged sword for majority of COVID-19 patients. Therefore, there is a need to identify ‘non-steroid’ potent and safe anti-inflammatory agents for use in therapeutic armamentarium against COVID-19. This article makes a case for one such existing drug, roflumilast, that can emerge as a steroid-sparing alternative against COVID-19.

Background to hypothesis

Within months of its outbreak, the COVID-19 pandemic has infected millions of people, claimed thousands of lives and disrupted economies of virtually all nations. Originating from the family of zoonotic viruses known as Coronavirus, SARS-CoV-2 is responsible for causing COVID-19, a highly contagious disease [1]. Following the Severe Acute Respiratory Syndrome (SARS) and Middle-East Respiratory Syndrome (MERS), COVID-19 becomes the third zoonotic disease caused by coronaviruses affecting humans, albeit more ferocious in terms of spread with no clinically proven or specific antiviral agent available for treatment [2].

COVID-19 has a median incubation period of around 5 days. Clinical presentation of COVID-19 varies from asymptomatic disease to symptomatic presentation consisting of fever, sore throat, cough, loss of taste or smell, headache, diarrhea, shortness of breath. Acute respiratory distress syndrome (ARDS), septic shock, acute cardiac injury, renal injury with fatal outcomes have been reported in severe COVID-19 [3].

SARS-CoV-2 infection causes activation of innate and adaptive immune system. However, a combination of excess inflammatory innate response and overactive adaptive immune response leads to harmful tissue damage. In this regard, cytokine storm, a severe immune-inflammatory response resulting from the release of several pro-inflammatory cytokines, is often considered as a mechanism behind severe complications of COVID-19 such as ARDS or multi-organ failure [4].

Statement of hypothesis

Accumulating data clearly indicates that large amounts of pro-inflammatory mediators such as Interleukin (IL)-6, IL-12, IL-18, IL-33, Tumor necrosis factor α (TNFα), Interferon (IFN)-α, IFNγ, IL-1β and several chemokines (CXCL-2, 3, 5, 8, 9, 10), are responsible for triggering the cytokine storm, hallmark of COVID-19 related complications [5]. Amongst these, Interleukin-6 (IL-6) is believed to play important pathogenic role in cytokine storm [6]. Raised IL-6 levels positively correlate with disease severity in COVID-19 patients [5]. In animal models of SARS-CoV infection, the inhibition of IL-6 has been shown to have mortality benefits and several anti-IL-6 receptor antibodies are being tested in COVID-19 patients [7]. Similar to IL-6, TNF-α is an important cytokine that plays crucial role in COVID-19 inflammatory response [8]. Colony-stimulating factors enhance the cytokine production by immune cells that further enhances inflammatory reaction. Chemokines are a group of cytokines secreted in viral infection and exert strong chemotactic effects. In animal models, anti-CXCL10 antibody has shown to attenuate lung injury, suggesting CXCL10 to be a critical chemokine in triggering ARDS. Similarly, raised levels of IL-8 in the circulation and in respiratory secretions of patients with ARDS can serve as a bio-marker to determine prognosis in COVID-19 patients [10].

Potent anti-inflammatory agents such as corticosteroids are being proposed to mitigate deleterious effects of cytokine storm in COVID-19 and many national treatment protocols have included such a recommendation [3,11]. The rationale behind corticosteroid use has been strengthened on the back of positive preliminary results from
RECOVERY trial [12] that showed use of dexamethasone led to lower mortality rate in hospitalized COVID-19 patients. However, it must be noted that steroids in viral infections can behave like a double-edged sword. e.g. corticosteroid therapy led to attenuation of viral clearance in SARS, MERS, influenza and appears to worsen clinical outcomes and increases propensity of bacterial infections and mortality [3]. As a result benefit:risk ratio of corticosteroids may not be uniform across varying disease severity of COVID-19 and their generalized use may cause more harm than benefits. Therefore, exploring ‘non-steroid’ agents that demonstrate desirable anti-inflammatory properties to mitigate cytokine storm but that are devoid of steroid related safety concerns is need of an hour in the fight against COVID-19.

In this context roflumilast, a Phosphodiesterase 4 (PDE4) inhibitor, deserves attention. PDE4 regulates pro-inflammatory cytokines and serves as an important modulator of airway inflammation. Inhibition of PDE4 causes cAMP accumulation which leads to favorable immune-modulating effects [13,14].

Need to test the hypothesis

Roflumilast is an orally administered PDE4 inhibitor approved in the EU, US and several countries in the world for treatment of chronic obstructive pulmonary disease (COPD). Abnormal immune response and severe respiratory inflammation are characteristics of COPD. Preclinical pharmacological studies demonstrate potent anti-inflammatory and immuno-modulatory effects of roflumilast. e.g. roflumilast potently inhibits PDE4 in neutrophils, macrophages, monocytes, dendritic cells, CD4+ and CD8+ T cells leading to anti-inflammatory effects, suppression of pro-inflammatory mediators, TNF-α synthesis and inhibition of cytokine production [15].

Roflumilast has shown to cause inhibition of major airway pro-inflammatory markers such as IL-4, IL-5, IL-6, IL-13, IL-17, IL-8, granulocyte-macrophage colony stimulating factor (GM-CSF) with reduction in levels of IL-1β, CCL-2, 3, 4 and CXCL10. Elevated CAMP due to roflumilast selectively inhibits a subset of pro-inflammatory mediators and increases level of anti-inflammatory cytokine (IL-10) to produce an overall potent and balanced anti-inflammatory effect [13]. Beneficial effects of roflumilast in terms of reduction in hypoxia [16], cytokine production and prevention of lung infiltration by immune cells have been demonstrated in animal models [17].

In-vivo data comparing roflumilast versus dexamethasone shows that unlike dexamethasone that non-specifically inhibits numerous mediators involved in inflammation and the immune response, roflumilast selectively inhibits a subset of pro-inflammatory mediators and growth factors [18]. Roflumilast has also shown to be useful in severe asthma exacerbations due to viral infections that cannot be sufficiently controlled by corticosteroids such as dexamethasone or fluticasone [19]. COPD patients with pronounced inflammation and advanced disease have shown better reduction in exacerbation risk observed with roflumilast in clinical studies [20]. Based on preliminary screening and prediction for anti-viral activity, a signal of possible anti-viral activity of roflumilast against SARS-Cov-2 cannot be ruled out [21].

Based on its established benefit:risk ratio in treatment of lung disorders and known mechanistic and pharmacological profile providing corroborative evidence of likely benefits in suppressing mediators involved in cytokine storm, there is adequate rationale to test whether roflumilast will emerge as a beneficial anti-inflammatory or immune modulating agent in the management of patients with COVID-19.

Compared to another PDE4 inhibitor apremilast (which is approved for treatment of psoriasis) [22], roflumilast has a long elimination half-life, convenient once daily dosing that does not require complex titration, reduced incidence of gastro-intestinal side-effects and close to a decade of clinical experience in management of inflammatory lung disorders such as COPD. Therefore, roflumilast is an ideal PDE4 inhibitor to be investigated further as a ‘steroid-sparing’ alternative in the treatment of patients with COVID-19.

Conclusion

Roflumilast may prove to be an important steroid-sparing anti-inflammatory agent in managing COVID-19 related immune-inflammatory manifestations and complications. Clinical trials to explore roflumilast as a monotherapy or in combination paradigm with standard of care or antivirals are hence warranted to establish place of this existing and safe drug in the treatment of patients across COVID-19 severity spectrum.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.mehy.2020.110246.

References

[1] Wang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents 2020;55(6):105948.
[2] De Savi C, Hughes DL, Kverno L. Quest for a COVID-19 cure by repurposing small-molecule drugs: mechanism of action, clinical development, synthesis at scale, and outlook for supply. Org Process Res Dev 2020;acs.oprd.0c00233. Published 2020 Jun 2. doi:10.1021/acs.oprd.0c00233.
[3] COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www. cdc.gov/drd/treatmentguidelines.nih.gov/. Accessed 24 July, 2020.
[4] Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol 2020;20:269–70.
[5] Li X, Greg M, Peng Y, Meng L, Shenim Lu. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 2020;10(2):102–8.
[6] Brocker C, Thompson D, Matsumoto A, Nebert DW, Vasthiou V. Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum Genomics 2010;5(1):30–55.
[7] Chakraborty C, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Agoramoothy G. COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients. J Med Virol 2020. https://doi.org/10.1002/jmv.26078.
[8] Carswell EA, Old LJ, Rassell RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Nail Acad Sci U S A 1975;72(9):3666–70.
[9] Hamilton JA. Colony-stimulating factors in inflammation and autoimmune. Nat Rev Immunol 2008;8(7):533–44.
[10] García-Laorden M, Lorente JA, Flores C, Slutsky AS, Villar J. Biomarkers for the acute respiratory distress syndrome: how to make the diagnosis more precise. Ann Trans Med 2017;5(14):283.
[11] Johnson Raymond M, Vinet JM. Dexamethasone in the management of covid-19. BMJ 2020;370(m2648).
[12] Elisabeth M. Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds. BMJ 2020;369(m2422).
[13] Zhang X, Chen Y, Fan I, Ye J, Fan J, Xu X, et al. Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap. Drug Des Devel Ther 2018;12:2371–9. https://doi.org/10.2147/DDDT.S165161.
[14] Konrad FM, Bury A, Schick MA, Ngamsonki RC, Reutenshan J. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation. PLoS ONE 2015;10(4). https://doi.org/10.1371/journal.pone.0121725. e0121725. Published 2015 Apr 24.
[15] Hatzellmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beune R, et al. The preclinical pharmacology of roflumilast – a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Palm Pharmacol Ther 2010;23(4):235–56.
[16] Izikii M, Raffestin B, Klar J, Hatzellmann A, Marx D, Tenor H, et al. Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hyperinflation in rats. J Pharmacol Exp Ther 2009;330(1):54–62.
[17] Bundschuh DS, Elsae M, Barig J, Wollen L, Hatzellmann A, Beune R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001;297(1):280–9.
[18] Herbert C, Hentiathachi A, Webb IC, Thomas PS, Foster PS, Kumar RK. Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma. Clin Exp Allergy 2008;38:847–56.
[19] Tilp C, Buecher H, Wex E, Erb K. Roflumilast but not dexamethasone or fluticasone
reduces neutrophilic airway inflammation and hyperreactivity in a murine influenza-induced asthma exacerbation model. Eur Respir J 2016;48(suppl 60). https://doi.org/10.1183/13993003.congress-2016.PA4893. [20] Rabe KF, Calverley PMA, Martinez FJ, Fabbri LM. Effect of roflumilast in patients with severe COPD and a history of hospitalization. Eur Respir J 2017;50(1):1700158.

[21] F Hu, J Jiang, P Yin. Prediction of potential commercially inhibitors against SARS-CoV-2 by multi-task deep model. arXiv preprint arXiv:2003.00728, 2020.

[22] Afra TP, Razmi TM, Dogra S. Apremilast in psoriasis and beyond: big hopes on a small molecule. Indian Dermatol Online J 2019;10(1):1–12.